Skip to content

High resistance levels seen in treated Ugandans: cost of therapy blamed

Truvada receives scientific approval in Europe

Once-daily abacavir receives approval in Europe

Infection with multi-drug resistant virus is lifelong, Canadian expert argues

Tenofovir/ddI: is CD4 cell loss on treatment linked to this combination?

Early virologic failure with ddI/tenofovir plus nevirapine or efavirenz

Kaletra effective and well tolerated in PI-experienced patients

Failure of three main classes of antiretrovirals present in 12% of EuroSIDA cohort

Roche will not go ahead with nelfinavir 625mg formulation in Europe: cites production problems